Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Post time 2026-10-17 01:17:22

journal：JAMA Neurology

Authors：Alicia Algeciras-Schimnich; Joshua A. Bornhorst; Daniel J. Figdore; Ramiro Eduardo Rea Reyes; Susan Ashrafzadeh-Kian; Rachel Wilson; Brian J. Burkett; Derek R. Johnson; Hugo Botha; Stuart J. McCarter; Gregory S. Day; Jonathan Graff-Radford; Vijay K. Ramanan; Clifford R. Jack; Sterling C. Johnson; Henrik Zetterberg; Ronald C. Petersen

Published date：2026-8-1

DOI：10.1001/jamaneurol.2026.1565

PDF link：https://jamanetwork.com/journals ... 786107799.14038.pdf

Article link：https://doi.org/10.1001/jamaneurol.2026.1565

Article Source：American Medical Association (AMA)。

Remark：

Post time 2026-10-17 01:17:23

: This post has been completed
Completed attachments will be deleted within 24 hours.

[JAMA] Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio

Best Answer

Same Category

Latest Reply

Announcement

Daily Top Contributors

[JAMA] Variability in Clinical Performance of the FDA-Cleared Lumipulse P-Tau217/β-Amyloid 1-42 Plasma Ratio Copy